Laman Utama87S • FRA
add
Roivant Sciences Ltd
Tutup sebelumnya
€23.97
Julat hari
€23.72 - €23.73
Julat tahun
€7.98 - €24.09
Permodalan pasaran
20.71B USD
Bilangan Purata
39.00
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Dis 2025info | Perubahan T/T |
|---|---|---|
Hasil | 2.00J | -77.83% |
Perbelanjaan pengendalian | 175.05J | 32.27% |
Pendapatan bersih | -265.89J | -256.98% |
Margin untung bersih | -13.30K | -808.17% |
Pendapatan bagi setiap syer | -0.24 | -20.57% |
EBITDA | -338.44J | -29.41% |
Kadar cukai berkesan | -8.04% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Dis 2025info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 4.53B | -11.98% |
Jumlah aset | 5.23B | -9.79% |
Jumlah liabiliti | 251.14J | -2.04% |
Jumlah ekuiti | 4.97B | — |
Syer tertunggak | 715.70J | — |
Harga kepada buku | 3.98 | — |
Pulangan pada aset | -16.48% | — |
Pulangan pada modal | -16.98% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Dis 2025info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -265.89J | -256.98% |
Tunai daripada operasi | -196.48J | 5.20% |
Tunai daripada pelaburan | 109.47J | -75.89% |
Tunai daripada pembiayaan | 328.19J | 220.24% |
Perubahan bersih dalam tunai | 241.61J | 988.44% |
Aliran tunai bebas | -88.76J | 70.76% |
Perihal
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel. Wikipedia
CEO
Diasaskan
7 Apr 2014
Tapak web
Pekerja
750
